Acurx Pharmaceuticals
ACXP
14 hedge funds and large institutions have $5.27M invested in Acurx Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.
13% more capital invested
Capital invested by funds: $4.66M → $5.27M (+$615K)
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.1% less ownership
Funds ownership: 0.67% → 0.57% (-0.1%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$9.87K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.42K |
| 3 |
BlackRock
New York
|
+$329 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$66 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$612K |
| 2 |
Millennium Management
New York
|
-$60.1K |
| 3 |
Mariner
Overland Park,
Kansas
|
-$48K |
| 4 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
-$37.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4.41K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $3.5M | -$612K | -9,300 | -17% |
|
|
DAM
2
Draper Asset Management
Smithtown,
New York
| $1.06M | – | – | – |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $307K | +$3.42K | +52 | +1% |
|
|
4
Millennium Management
New York
| $116K | -$60.1K | -914 | -39% |
|
|
TWC
5
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $77.4K | -$37.3K | -567 | -38% |
|
|
6
BlackRock
New York
| $62.2K | +$329 | +5 | +0.6% |
|
7
Osaic Holdings
Scottsdale,
Arizona
| $48K | – | – | – |
|
|
TAM
8
Tocqueville Asset Management
New York
| $40.2K | – | – | – |
|
|
SFA
9
Semmax Financial Advisors
Winston Salem,
North Carolina
| $24K | – | – | – |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $12K | – | – | – |
|
|
BAM
11
Belpointe Asset Management
Reno,
Nevada
| $11.9K | +$9.87K | +150 | New |
|
|
12
UBS Group
Zurich,
Switzerland
| $10.9K | -$4.41K | -67 | -33% |
|
13
Wells Fargo
San Francisco,
California
| $243 | – | – | – |
|
|
14
Bank of America
Charlotte,
North Carolina
| $40 | +$66 | +1 | New |
|
|
15
Mariner
Overland Park,
Kansas
| – | -$48K | -800 | Closed |
|
ACXP Hedge Fund Activity: Q4 2022 in Review
14 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q4 2022, worth a combined $5.27M — up 13% from $4.66M a quarter earlier.
Fund positioning in ACXP was balanced in Q4 2022: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 4 trimmed.
The largest buyer was Belpointe Asset Management, opening a new position worth an estimated $9.87K. The largest seller was Armistice Capital, cutting an estimated $612K.
- 14 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $5.27M of Acurx Pharmaceuticals stock for Q4 2022, up 13% quarter-over-quarter.
- 2 funds opened new Acurx Pharmaceuticals positions in Q4 2022 and 2 closed out, a net change of 0 holders.
- The largest Acurx Pharmaceuticals buyer in Q4 2022 was Belpointe Asset Management, an estimated $9.87K added.
- The largest Acurx Pharmaceuticals seller in Q4 2022 was Armistice Capital, an estimated $612K sold.
Based on aggregated 13F filings for Q4 2022.